Tetrahydrobiopterin is an essential cofactor for NO production. 
C ardiovascular diseases pose a considerable societal and economic burden on health care systems (1) . Such diseases are usually associated with functional and structural changes within the vascular network as well as concomitant increases in oxidative stress (2) . Endothelial dysfunction is characterized by impaired vasodilation, mainly due to loss of nitric oxide (NO) signaling (3, 4) . NO biosynthesis in the vasculature is primarily catalyzed by endothelial nitric oxide synthase (eNOS) (5) , and tetrahydrobiopterin (BH 4 ) is an essential cofactor for all 3 isoforms of NOS (6, 7) . When BH 4 bioavailability is limited, NOS may become "uncoupled," producing superoxide at the expense of NO, thereby potentiating oxidative stress (8) .
Thus, raising endothelial BH 4 levels has been suggested as a strategy to maintain healthy NO production and bioavailability at the level of the endothelium (9, 10) . To support this, intra-arterial administration of BH 4 improves endothelial dysfunction in patients with hypertension (11) , coronary artery disease (12) , and hypercholesterolemia (13) .
However, due to its unstable nature, orally administered BH 4 (or its analogue sapropterin) has limited efficacy in improving vascular hemodynamics (14) (15) (16) .
Therefore, other strategies to raise endogenous BH 4 bioavailability at the level of the endothelium are desirable.
BH 4 is synthesized from GTP in a reaction where the committing step is mediated by GTP cyclohydrolase-1 (GCH1) (17) . Modulation of GCH1 expression has been shown to regulate BH 4 , NO, and cardiovascular function (18) (19) (20) . GCH1 is subject to feed-forward regulation by L-phenylalanine (L-phe), via an allosteric protein interaction with GCH1 feedback regulatory protein (GFRP) (21, 22) . This GCH1-GFRP complex is operative in humans because oral challenge with L-phe leads to a 3-fold rise in plasma biopterin levels (a correlate of BH 4 )-an effect that is attenuated in patients with a loss-of-function GCH1 mutation (23) . Targeting endogenous BH 4 biosynthesis, by activating the GCH1-GFRP axis pharmacologically, thus represents a method to enhance vascular BH 4 levels at the level of the endothelium, circumventing the poor bioavailability following oral BH 4 administration (14, 24) .
To support this hypothesis, it is known the GCH1-GFRP axis regulates BH 4 and NO in endothelial cells (25) . Overexpression of GFRP reduces basal BH 4 levels (26) and attenuates the rise in BH 4 and NO that occurs in response to a proinflammatory stimulus (27) .
Additionally, the primary source of BH 4 appears to be derived from GCH1 localized within the vascular endothelium, and GFRP is coexpressed within these cells (28, 29) . Finally, oral L-phe elicits a rise in vascular BH 4 -an effect that is absent in mice lacking endothelial GCH1 (24) .
The GCH1-GFRP axis thus ensures that BH 4 levels are kept within a tight physiological range. However, the crucial mechanistic link between GCH1-GFRP activation by L-phe, the concomitant rise in BH 4 and its potential impact on NO and vascular function is lacking. The aim of this study was to determine whether L-phe raises vascular BH 4 levels by activating the GCH1-GFRP complex in vivo and improves endothelial function in an animal model of essential hypertension.
METHODS
Further details of all assays can be found in the Supplemental Methods.
EFFECT OF L-PHE ON RECOMBINANTLY EXPRESSED
GCH-1 ACTIVITY. A kinetic microplate assay was used to determine the effects of L-phe (1 mmol$l À1 ) on the activity of recombinantly expressed human GCH1
(0.1 mmol$l À1 ) either alone or when coincubated with legend, or in the Supplemental Table 2 . Table 2 ). BH 2 ¼ dihydrobiopterin; BH 4 ¼ tetrahydrobiopterin; eNOS ¼ endothelial nitric oxide synthase;
RESULTS

EFFECTS OF L-PHE ON RECOMBINANT GCH1 ACTIVITY (IN VITRO) AND SYSTEMIC BH 4 AND NITRITE (IN VIVO).
As previously described (24, 30) , the combination of purified recombinant GFRP with GCH1 protein had a higher basal activity than GCH1 alone in vitro. The addition of L-phe (2 mmol$l À1 ) had no effect on purified GCH1 activity alone but caused a significant rise in GCH1 activity when coincubated with GFRP, confirming that L-phe is an allosteric regulator of the GCH1-GFRP complex only ( Figure 1A ).
In vivo, oral L-phe (100 mg$kg À1 ) bolus to WKY and SHR significantly increased plasma BH 4 levels within 30 min, and levels returned back to baseline within 4 h ( Figure 1B) . Correspondingly, a significant rise in nitrite levels was also detected within 30 min, but whereas this returned to baseline in WKY, it remained elevated in SHR for at least 4 h ( Figure 1C) .
Interestingly, there were no statistically significant differences in BH 2 and biopterin in all groups although trend increases were observed ( Figures 1D   and 1E ). Heikal et al.
EFFECTS OF BOLUS AND LONG-TERM L-PHE ON
values ( Figure 2B ). There were no statistically significant differences in BH 2 Figure 3A) . As anticipated, superoxide levels were higher basally in SHR compared with WKY ( Figure 3B) .
Bolus dose or long-term administration of L-phe significantly reduced superoxide levels in SHR ( Figure 3B ). Superoxide dismutase, the positive control, reduced superoxide in all study groups ( Figure 3B ). Again, we observed no significant changes in BH 2 or biopterin in aortic tissue AE L-phe administration ( Figures 3C and 3D) . Unfortunately, in aortic tissues, nitrite levels fell below the limit of detection and were therefore not quantifiable. other abbreviations as in Figure 1 . Thus, there is still much work to be undertaken to improve the efficacy and safety of pharmacotherapies that enhance NO bioavailability, but our present study provides the first proof-of-concept data that the GCH1-GFRP complex is a rational therapeutic target to achieve BH 4 elevation and NO restoration within blood vessels.
Heikal et al. J A C C : B A S I C T O T R A N S L A T I O N A L S C I E
To translate these findings further, we propose 2 parallel research strategies. The first clinical development strategy would investigate the impact of Lphe administration on vascular function using flow mediated dilatation, in patients with existing endothelial dysfunction versus healthy controls. It may be predicted that flow-mediated dilatation would be improved in the patient cohort, whereas negligible effect would be seen in the nonpatient controls.
However, L-phe, as a therapy, may have challenges given its diverse biological activity, raising potential safety concerns, and these would need to be concomitantly investigated in trial participants. The second parallel strategy would be focused around 
